Review



mek1 2  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bioss mek1 2
    Overexpression of CRAF activates the RAF/MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) <t>MEK1,</t> (E) MEK2, (F) ERK1and (G) ERK2. Western blotting was used to analyze the protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) <t>MEK1/2,</t> (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.
    Mek1 2, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/MEK1+2+Polyclonal+Antibody/pmc13122582-85-27-45
    Average 94 stars, based on 3 article reviews
    mek1 2 - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade"

    Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade

    Journal: Molecular Medicine Reports

    doi: 10.3892/mmr.2026.13881

    Overexpression of CRAF activates the RAF/MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1and (G) ERK2. Western blotting was used to analyze the protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.
    Figure Legend Snippet: Overexpression of CRAF activates the RAF/MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1and (G) ERK2. Western blotting was used to analyze the protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.

    Techniques Used: Over Expression, Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Negative Control

    Overexpression of RUVBL1 activates the MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1 and (G) ERK2. Western blotting was used to analyze protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. RUVBL1, RuvB-like AAA ATPase-1; p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.
    Figure Legend Snippet: Overexpression of RUVBL1 activates the MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1 and (G) ERK2. Western blotting was used to analyze protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. RUVBL1, RuvB-like AAA ATPase-1; p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.

    Techniques Used: Over Expression, Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Negative Control

    Related Articles

    Over Expression:

    Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade
    Article Snippet: Color development was performed using an ECL kit (cat. no. P0018; Beyotime Biotechnology).

    Reverse Transcription:

    Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade
    Article Snippet: Color development was performed using an ECL kit (cat. no. P0018; Beyotime Biotechnology).

    Real-time Polymerase Chain Reaction:

    Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade
    Article Snippet: Color development was performed using an ECL kit (cat. no. P0018; Beyotime Biotechnology).

    Expressing:

    Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade
    Article Snippet: Color development was performed using an ECL kit (cat. no. P0018; Beyotime Biotechnology).

    Western Blot:

    Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade
    Article Snippet: Color development was performed using an ECL kit (cat. no. P0018; Beyotime Biotechnology).

    Negative Control:

    Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade
    Article Snippet: Color development was performed using an ECL kit (cat. no. P0018; Beyotime Biotechnology).



    Similar Products

    anti phospho mek1  (MedChemExpress)
    94
    MedChemExpress anti phospho mek1
    Anti Phospho Mek1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/Phospho-MEK1%2F2(Ser217%2F221)+Antibody/pmc13361411-251-44-46
    Average 94 stars, based on 1 article reviews
    anti phospho mek1 - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    mek1 2  (ABclonal Biotechnology)
    95
    ABclonal Biotechnology mek1 2
    IL‐35 induces the MAPK/ERK signaling pathway, thereby enhancing eNOS Ser1177 phosphorylation and NO production in endothelial cells. (A) Volcano plot of eNOS‐interacting proteins in HUVECs (PA vs. PA + IL‐35) by IP‐mass spectrometry. Red dots: upregulated in PA + IL‐35 group (fold change > 1.5, p < 0.05); MAPK3 (ERK1) is highlighted. (B) STRING‐based PPI network of top 20 binding proteins. ERK1 is the only direct interactor with eNOS. (C) Western blot bands of p‐cRAF, p‐MEK, p‐ERK, p‐eNOS (Ser1177), and total proteins in HUVECs. (D–G) Densitometric analysis of p‐cRAF, p‐MEK, p‐ERK, and p‐eNOS (Ser1177) normalized to total proteins, n = 3. (H, I) NO fluorescence intensity in HUVECs (H, scale bar = 50 μM) with semi‐quantification (I, n = 3). Data are mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Mek1 2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/MEK1%2FMEK2+Rabbit+mAb/pmc13689533-35-43-53
    Average 95 stars, based on 1 article reviews
    mek1 2 - by Bioz Stars, 2026-11
    95/100 stars
    		  Buy from Supplier
    mek1 2  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc mek1 2
    IL‐35 induces the MAPK/ERK signaling pathway, thereby enhancing eNOS Ser1177 phosphorylation and NO production in endothelial cells. (A) Volcano plot of eNOS‐interacting proteins in HUVECs (PA vs. PA + IL‐35) by IP‐mass spectrometry. Red dots: upregulated in PA + IL‐35 group (fold change > 1.5, p < 0.05); MAPK3 (ERK1) is highlighted. (B) STRING‐based PPI network of top 20 binding proteins. ERK1 is the only direct interactor with eNOS. (C) Western blot bands of p‐cRAF, p‐MEK, p‐ERK, p‐eNOS (Ser1177), and total proteins in HUVECs. (D–G) Densitometric analysis of p‐cRAF, p‐MEK, p‐ERK, and p‐eNOS (Ser1177) normalized to total proteins, n = 3. (H, I) NO fluorescence intensity in HUVECs (H, scale bar = 50 μM) with semi‐quantification (I, n = 3). Data are mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Mek1 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/MEK1%2F2+Antibody/pm42878952-59-4-17
    Average 96 stars, based on 1 article reviews
    mek1 2 - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    mek1 2  (Proteintech)
    94
    Proteintech mek1 2
    IL‐35 induces the MAPK/ERK signaling pathway, thereby enhancing eNOS Ser1177 phosphorylation and NO production in endothelial cells. (A) Volcano plot of eNOS‐interacting proteins in HUVECs (PA vs. PA + IL‐35) by IP‐mass spectrometry. Red dots: upregulated in PA + IL‐35 group (fold change > 1.5, p < 0.05); MAPK3 (ERK1) is highlighted. (B) STRING‐based PPI network of top 20 binding proteins. ERK1 is the only direct interactor with eNOS. (C) Western blot bands of p‐cRAF, p‐MEK, p‐ERK, p‐eNOS (Ser1177), and total proteins in HUVECs. (D–G) Densitometric analysis of p‐cRAF, p‐MEK, p‐ERK, and p‐eNOS (Ser1177) normalized to total proteins, n = 3. (H, I) NO fluorescence intensity in HUVECs (H, scale bar = 50 μM) with semi‐quantification (I, n = 3). Data are mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Mek1 2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/MEK1-Specific+Antibody/pm42869130-86-55-72
    Average 94 stars, based on 1 article reviews
    mek1 2 - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    p mek1 2  (ABclonal Biotechnology)
    94
    ABclonal Biotechnology p mek1 2
    IL‐35 induces the MAPK/ERK signaling pathway, thereby enhancing eNOS Ser1177 phosphorylation and NO production in endothelial cells. (A) Volcano plot of eNOS‐interacting proteins in HUVECs (PA vs. PA + IL‐35) by IP‐mass spectrometry. Red dots: upregulated in PA + IL‐35 group (fold change > 1.5, p < 0.05); MAPK3 (ERK1) is highlighted. (B) STRING‐based PPI network of top 20 binding proteins. ERK1 is the only direct interactor with eNOS. (C) Western blot bands of p‐cRAF, p‐MEK, p‐ERK, p‐eNOS (Ser1177), and total proteins in HUVECs. (D–G) Densitometric analysis of p‐cRAF, p‐MEK, p‐ERK, and p‐eNOS (Ser1177) normalized to total proteins, n = 3. (H, I) NO fluorescence intensity in HUVECs (H, scale bar = 50 μM) with semi‐quantification (I, n = 3). Data are mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
    P Mek1 2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/Phospho-MAP2K1-S298+Rabbit+pAb/pm42350549-126-63-64
    Average 94 stars, based on 1 article reviews
    p mek1 2 - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    mek inhibitor mek1 2 inhibitor pd 0325901  (MedChemExpress)
    96
    MedChemExpress mek inhibitor mek1 2 inhibitor pd 0325901
    IL‐35 induces the MAPK/ERK signaling pathway, thereby enhancing eNOS Ser1177 phosphorylation and NO production in endothelial cells. (A) Volcano plot of eNOS‐interacting proteins in HUVECs (PA vs. PA + IL‐35) by IP‐mass spectrometry. Red dots: upregulated in PA + IL‐35 group (fold change > 1.5, p < 0.05); MAPK3 (ERK1) is highlighted. (B) STRING‐based PPI network of top 20 binding proteins. ERK1 is the only direct interactor with eNOS. (C) Western blot bands of p‐cRAF, p‐MEK, p‐ERK, p‐eNOS (Ser1177), and total proteins in HUVECs. (D–G) Densitometric analysis of p‐cRAF, p‐MEK, p‐ERK, and p‐eNOS (Ser1177) normalized to total proteins, n = 3. (H, I) NO fluorescence intensity in HUVECs (H, scale bar = 50 μM) with semi‐quantification (I, n = 3). Data are mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Mek Inhibitor Mek1 2 Inhibitor Pd 0325901, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/Mirdametinib/bio_rxiv__64898__2026__06__19__733436-285-28-40
    Average 96 stars, based on 1 article reviews
    mek inhibitor mek1 2 inhibitor pd 0325901 - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    p mek1 2  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc p mek1 2
    IL‐35 induces the MAPK/ERK signaling pathway, thereby enhancing eNOS Ser1177 phosphorylation and NO production in endothelial cells. (A) Volcano plot of eNOS‐interacting proteins in HUVECs (PA vs. PA + IL‐35) by IP‐mass spectrometry. Red dots: upregulated in PA + IL‐35 group (fold change > 1.5, p < 0.05); MAPK3 (ERK1) is highlighted. (B) STRING‐based PPI network of top 20 binding proteins. ERK1 is the only direct interactor with eNOS. (C) Western blot bands of p‐cRAF, p‐MEK, p‐ERK, p‐eNOS (Ser1177), and total proteins in HUVECs. (D–G) Densitometric analysis of p‐cRAF, p‐MEK, p‐ERK, and p‐eNOS (Ser1177) normalized to total proteins, n = 3. (H, I) NO fluorescence intensity in HUVECs (H, scale bar = 50 μM) with semi‐quantification (I, n = 3). Data are mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
    P Mek1 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/Phospho-MEK1%2F2+(Ser217%2F221)+Rabbit+mAb/pmc13042271-96-74-79
    Average 96 stars, based on 1 article reviews
    p mek1 2 - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    mek1 2  (Bioss)
    94
    Bioss mek1 2
    Overexpression of CRAF activates the RAF/MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) <t>MEK1,</t> (E) MEK2, (F) ERK1and (G) ERK2. Western blotting was used to analyze the protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) <t>MEK1/2,</t> (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.
    Mek1 2, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/MEK1+2+Polyclonal+Antibody/pmc13122582-85-27-45
    Average 94 stars, based on 1 article reviews
    mek1 2 - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    phospho mek1 2  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc phospho mek1 2
    Overexpression of CRAF activates the RAF/MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) <t>MEK1,</t> (E) MEK2, (F) ERK1and (G) ERK2. Western blotting was used to analyze the protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) <t>MEK1/2,</t> (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.
    Phospho Mek1 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mek1+2/pmc13042271-44-21-41
    Average 86 stars, based on 1 article reviews
    phospho mek1 2 - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    IL‐35 induces the MAPK/ERK signaling pathway, thereby enhancing eNOS Ser1177 phosphorylation and NO production in endothelial cells. (A) Volcano plot of eNOS‐interacting proteins in HUVECs (PA vs. PA + IL‐35) by IP‐mass spectrometry. Red dots: upregulated in PA + IL‐35 group (fold change > 1.5, p < 0.05); MAPK3 (ERK1) is highlighted. (B) STRING‐based PPI network of top 20 binding proteins. ERK1 is the only direct interactor with eNOS. (C) Western blot bands of p‐cRAF, p‐MEK, p‐ERK, p‐eNOS (Ser1177), and total proteins in HUVECs. (D–G) Densitometric analysis of p‐cRAF, p‐MEK, p‐ERK, and p‐eNOS (Ser1177) normalized to total proteins, n = 3. (H, I) NO fluorescence intensity in HUVECs (H, scale bar = 50 μM) with semi‐quantification (I, n = 3). Data are mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Immunity, Inflammation and Disease

    Article Title: Interleukin‐35 Ameliorates Obesity‐Associated Impairment of Endothelium‐Dependent Vasodilation via the STAT3‐MAPK/ERK‐eNOS Signaling Axis

    doi: 10.1002/iid3.70564

    Figure Lengend Snippet: IL‐35 induces the MAPK/ERK signaling pathway, thereby enhancing eNOS Ser1177 phosphorylation and NO production in endothelial cells. (A) Volcano plot of eNOS‐interacting proteins in HUVECs (PA vs. PA + IL‐35) by IP‐mass spectrometry. Red dots: upregulated in PA + IL‐35 group (fold change > 1.5, p < 0.05); MAPK3 (ERK1) is highlighted. (B) STRING‐based PPI network of top 20 binding proteins. ERK1 is the only direct interactor with eNOS. (C) Western blot bands of p‐cRAF, p‐MEK, p‐ERK, p‐eNOS (Ser1177), and total proteins in HUVECs. (D–G) Densitometric analysis of p‐cRAF, p‐MEK, p‐ERK, and p‐eNOS (Ser1177) normalized to total proteins, n = 3. (H, I) NO fluorescence intensity in HUVECs (H, scale bar = 50 μM) with semi‐quantification (I, n = 3). Data are mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: Primary antibodies for immunofluorescence and Western blotting: EBI3 (12371‐1‐AP), IL‐12A (85754‐2‐RR), platelet endothelial cell adhesion molecule‐1 (PECAM‐1/CD31) (11265‐1‐AP), eNOS (27120‐1‐AP), and β‐tubulin (66240‐1‐Ig) from Proteintech (USA); p‐eNOS (Ser1177, #9571), p‐cRAF (#9427), p‐MEK1/2 (#9154), and p‐STAT3 (#9145) from Cell Signaling Technology (USA); cRAF (A19638), MEK1/2 (A4868), p‐ERK1/2 (AP0974), ERK1/2 (A4782), and STAT3 (A1192) from ABclonal Technology (China).

    Techniques: Phospho-proteomics, Mass Spectrometry, Binding Assay, Western Blot, Analysis, Fluorescence

    IL‐35 activates the STAT3‐MAPK/ERK‐eNOS signaling axis to promote eNOS phosphorylation and NO production in endothelial cells. (A) Western blot bands of p‐STAT3, p‐eNOS (Ser1177), p‐cRAF, p‐MEK, p‐ERK, and corresponding total proteins in HUVECs. (B–I) Densitometric analysis of p‐STAT3, STAT3, p‐eNOS (Ser1177), eNOS, p‐cRAF, p‐MEK, and p‐ERK normalized to total proteins or β‐tubulin, n = 3. (J–K) NO fluorescence intensity in HUVECs (J, scale bar = 50 μM) with semi‐quantification (K, n = 3). Data are mean ± SD. ns, not significant; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Journal: Immunity, Inflammation and Disease

    Article Title: Interleukin‐35 Ameliorates Obesity‐Associated Impairment of Endothelium‐Dependent Vasodilation via the STAT3‐MAPK/ERK‐eNOS Signaling Axis

    doi: 10.1002/iid3.70564

    Figure Lengend Snippet: IL‐35 activates the STAT3‐MAPK/ERK‐eNOS signaling axis to promote eNOS phosphorylation and NO production in endothelial cells. (A) Western blot bands of p‐STAT3, p‐eNOS (Ser1177), p‐cRAF, p‐MEK, p‐ERK, and corresponding total proteins in HUVECs. (B–I) Densitometric analysis of p‐STAT3, STAT3, p‐eNOS (Ser1177), eNOS, p‐cRAF, p‐MEK, and p‐ERK normalized to total proteins or β‐tubulin, n = 3. (J–K) NO fluorescence intensity in HUVECs (J, scale bar = 50 μM) with semi‐quantification (K, n = 3). Data are mean ± SD. ns, not significant; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Article Snippet: Primary antibodies for immunofluorescence and Western blotting: EBI3 (12371‐1‐AP), IL‐12A (85754‐2‐RR), platelet endothelial cell adhesion molecule‐1 (PECAM‐1/CD31) (11265‐1‐AP), eNOS (27120‐1‐AP), and β‐tubulin (66240‐1‐Ig) from Proteintech (USA); p‐eNOS (Ser1177, #9571), p‐cRAF (#9427), p‐MEK1/2 (#9154), and p‐STAT3 (#9145) from Cell Signaling Technology (USA); cRAF (A19638), MEK1/2 (A4868), p‐ERK1/2 (AP0974), ERK1/2 (A4782), and STAT3 (A1192) from ABclonal Technology (China).

    Techniques: Phospho-proteomics, Western Blot, Analysis, Fluorescence

    Overexpression of CRAF activates the RAF/MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1and (G) ERK2. Western blotting was used to analyze the protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.

    Journal: Molecular Medicine Reports

    Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade

    doi: 10.3892/mmr.2026.13881

    Figure Lengend Snippet: Overexpression of CRAF activates the RAF/MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1and (G) ERK2. Western blotting was used to analyze the protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.

    Article Snippet: The antibodies were as follows: GAPDH (1:1,000; cat. no. P30008M; Abmart Pharmaceutical Technology Co., Ltd.), A-Raf proto-oncogene serine/threonine-protein kinase (ARAF) (cat. no. bs-2251R), CRAF (cat. no. bs-23170R), MEK1/2 (cat. no. bs-1041R), phosphorylated (p)-MEK1/2 (cat. no. bs-3270R), ERK1/2 (cat. no. bsm-33232M), p-ERK1/2 (cat. no. bs-3016R; all BIOSS), RUVBL1 (cat. no. 74775; Cell Signaling Technology, Inc.), ERK1/2 (all 1:500; cat. no. bsm-33232M; BIOSS), B-Raf proto-oncogene serine/threonine-protein kinase (BRAF) (1:2,000; cat. no. ab33899; Abcam) and HRP-conjugated universal secondary antibody [cat. nos.

    Techniques: Over Expression, Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Negative Control

    Overexpression of RUVBL1 activates the MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1 and (G) ERK2. Western blotting was used to analyze protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. RUVBL1, RuvB-like AAA ATPase-1; p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.

    Journal: Molecular Medicine Reports

    Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade

    doi: 10.3892/mmr.2026.13881

    Figure Lengend Snippet: Overexpression of RUVBL1 activates the MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1 and (G) ERK2. Western blotting was used to analyze protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. RUVBL1, RuvB-like AAA ATPase-1; p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.

    Article Snippet: The antibodies were as follows: GAPDH (1:1,000; cat. no. P30008M; Abmart Pharmaceutical Technology Co., Ltd.), A-Raf proto-oncogene serine/threonine-protein kinase (ARAF) (cat. no. bs-2251R), CRAF (cat. no. bs-23170R), MEK1/2 (cat. no. bs-1041R), phosphorylated (p)-MEK1/2 (cat. no. bs-3270R), ERK1/2 (cat. no. bsm-33232M), p-ERK1/2 (cat. no. bs-3016R; all BIOSS), RUVBL1 (cat. no. 74775; Cell Signaling Technology, Inc.), ERK1/2 (all 1:500; cat. no. bsm-33232M; BIOSS), B-Raf proto-oncogene serine/threonine-protein kinase (BRAF) (1:2,000; cat. no. ab33899; Abcam) and HRP-conjugated universal secondary antibody [cat. nos.

    Techniques: Over Expression, Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Negative Control